## REFERENCES

- Adhikary L, et al. Abnormal p38mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004; 47:1210–1222.
- Aguirre V, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002; 277:1531–1537.
- Aguirre V, et al. The c-Jun NH(2)- terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-9054.
- Ahima RS, Flier JS Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11: 327–332.
- Alessi MC, et al.. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
- Arai T, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994; 14:1129–1136.
- Araki T, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism. 2006; 55: 996–1001.
- Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expressionin human monocyte- derived macrophages. Circulation 2001;103: 1057–1063
- Arita Y, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophy Res Commun 1999; 257: 79-83.
- Arkan MC, et al. IKK-beta links infl ammation to obesity-induced insulin resistance. Nat Med, 2005; 11:191–198.
- Aso Y, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006; 55: 1954-1960.
- Atzmon G, et al. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 2002;34:622–628.
- Balagopal P, et al. Reduction of Elevated Serum Retinol Binding Protein (RBP4) in Obese Children by Lifestyle Intervention: Association with Sub-clinical Inflammation *J Clin Endocrin Metab.*2007; 92:1971-1974.

- Baratta R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004; 89: 2665-2671.
- Barrett-Connor E and Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–1867,
- Barter PJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160–167.
- Barzilai N, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999; 48: 94 98.
- Bastard JP, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
- Basualdo CG, et al. Vitamin A (retinol) status of First Nation adults with non-insulin-dependent diabetes mellitus. *J Am Coll Nutr* 1997; 16: 39-45.
- Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999; 48:1–9.
- Bennett CN, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005; 102: 3324–3329.
- Bensaid M et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.
- Berg AH, et al. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab. 2004; 287: E1178–E1188.
- Berg AH, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947–953
- Berg AH, Scherer PE. Adipose Tissue, Inflammation, and Cardiovascular Disease. *Circ Res.* 2005; 96: 939-49.
- Berger J and Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 2002; 53, 409–435
- Bergman RN, Mittelman SD. Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998; 9:205–221.
- Bermúdez-Siva FJ et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531: 282–284.
- Bhagar K and Vallance P. Inflammatory cytokines impairs endothelium- dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042– 3047
- Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992;12: 647–656.

- Blake, GJ, Ridker PM. Novel Clinical Markers of Vascular Wall Inflammation. Circ Res. 2001; 89: 763-771
- Bluher M, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053–3060.
- Bodzioch M, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347-551
- Bokarewa M, et al. Resistin an adipokine with potent pro-inflammatory properties. J Immunol 2005;174: 5789–5795.
- Boring L, et al. Decreased lesion formation in CCR2 ko mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.
- Bottner A, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053-4061.
- Bouhlel MA, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab, 2007; 6: 137–143.
- Branen L, et al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24:2137–2142.
- Brendle DC, et al. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol 2001; 87: 324–329.
- Brentano F, et al. Pre B cell colony enhancing factor/ visfatin a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix degrading activities. Arthritis. Rheum. 2007; 56: 2829-2839.
- Brochu M, et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism. 2003; 52: 599–604.
- Bruun JM, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-33.
- Burnett MS, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182: 241-8.
- Busso N, et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 2002;168:875–882.
- Butte NF, et al. Genetic and environmental factors influencing fasting serum adiponectin in Hispanic children. J Clin Endocrinol Metab 2005; 90: 4170-4176.
- Cai D, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 2005; 11:183–190.
- Cai Q, et al. Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis Am J Physiol 2004; 287:C707– C714,

- Calabro P, et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-1113.
- Caldefie-Chezet F, et al. Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic Res 2003; 37: 809–814.
- Caldefie-Chezet F, et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 2001; 69: 414–418.
- Calles-Escandon J, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998, 47:290–293.
- Campbell JH, Campbell GR: Cell biology of atherosclerosis. J Hypertension 1994, 12:S129-S132.
- Campbell LA, Kuo CC. Chlamydia pneumoniae: an infectious risk factor for atherosclerosis? Nat Rev Microbiol. 2004; 2: 23–32.
- Canault M, et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004;172: 211–218.
- Cao Z, et al. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991; 5:1538-1352
- Cawthorn WP, et al. Tumour necrosis factor-alpha inhibits adipogenesis via a betacatenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 2007;14:1361-1373.
- Charriere G, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278:9850 –9855.
- Chawla A, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48–52.
- Chen H, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003; 278: 45021-- 6.
- Chen Z, et al. Troglitazone inhibits atherosclerosis in apoli- Arterioscler Thromb Vasc Biol 2001; 21:372–377.
- Cho YM, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461.
- Choi KC, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005; 28: 747-753
- Chowdhury B, et al. A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord. 1994;18:219–234.

- Christiansen T, et al. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes 2005; 29: 146-150.
- Chu X, et al. Suppression of adipogenesis program in cultured preadipocytes transfected stably with cyclooxygenase isoforms. Biochim Biophys Acta. 2009; 1791: 273-280.
- Chu X, et al. Up-regulation of adipogenesis in adipocytes expressing stably cyclooxygenase-2 in the antisense direction. Prostaglandins Other Lipid Mediat. 2010; 91:1-9.
- Chung S, et al Preadipocytes Mediate Lipopolysaccharide-Induced Inflammation and Insulin Resistance in Primary Cultures of Newly Differentiated Human Adipocytes. Endocrinology. 2006; 147: 5340–5351.
- Cinti S, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res, 2005; 46: 2347–2355.
- Clarkson P, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999; 33:1379–1385.
- Cnop M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
- Collins AR, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21:365–371
- Combs, T.P. et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367–383
- Considine RV, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292–295.
- Cooke JP and Oka RK. Does leptin cause vascular disease? Circulation 2002;106: 1904-1905.
- Cota D et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
- Cousin B, et al. A role for preadipocytes as macrophage-like cells. FASEB J, 1999 ; 13: 305–312.
- Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 2004; 4: 572–579.
- Cowie CC, et al. Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999–2000. MMWR 2003; 52: 833–837.
- Croci T, et al. Role of cannabinoid CB1 receptors and tumor necrosis factor-a in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents. Br. Journal. Pharmacol. 2003; 140:115–122.

- Dahl TB, et al. Increased expression of visfatin in macrophage of human unstable carotid and coronary atherosclerosis. Circulation 2007; 115: 972-980.
- Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am. J. Cardiol. 2002; 90: 27–33.
- Dandona P, et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83:2907–2910
- Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000; 26: 13.
- de Lemos JA, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-695.
- de Souza CJ, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863–1871.
- Dekker JM, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489-1496.
- Delaigle AM, et al. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004;145, 5589–5597.
- Despres JP, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121–2134.
- Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 2000; 29:790-2.
- Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585–589.
- Diep QN, et al. Long-term effects of the PPAR gamma activator pioglitazoneglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol. 2004; 82: 976-985.
- Dietze-Schroeder D, et al. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005; 54: 2003-2011.
- Dol-Gleizes F, et al. Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice. Arteriosclerosis Thrombosis and Vascular Biology 2009; 29: 12-18.
- Doll R and Hill AB. Lung cancer and other causes of death in relation to smoking: a second report on the mortality of British doctors. Br Med 1956; J 2: 1071–1081

- Dusserre E, et al. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000; 1500: 88–96
- Dutta K, et al. Repeated systemic Escherichia coli infection enhances anti-oxidant response in hypercholesterolemic mice inducing cardiovascular inflammation. Inflammation 2009; 32: 89-98.
- Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 1997; **96**: 3248–50.

Ehtisham NZ: Do resistin resist insulin? Curr Sci 2002, 83:1190–1191.

- Elgazar-Carmon V, Rudich A, Hadad N, et al. 2008. Neutrophils transiently infi ltrate intraabdominal fat early in the course of high fat feeding. J Lipid Res, 49:1894–903.
- Engelberts I, et al. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 515-516.
- Engell SJ, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838–2843

English JP, et al. Tobacco and coronary disease. JAMA 1940;115: 1327-1329

- Eriksson P, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65-71.
- Eriksson P, et al. Regional variation in plasmin-ogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000; 83: 545–548
- Erikstrup C, et al. Retinol-Binding Protein 4 and Insulin Resistance. N Engl J Med 2006; 355:1393-1394
- Esposito K, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
- Faggioni R, et al. Leptin deficiency enhances sensitivity to endotoxin induced lethality. Am J Physiol 1999; 276:136–142.
- Faggioni R, et al. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001; 14: 2565–2571.
- Fain JN, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–2282.
- Farooqi IS, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093–1103.
- Fasshauer M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003; 301, 1045–1050

- Fehmann H, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002; 34: 671-673.
- Filippatos TD, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30:323–326.
- Fleming RM. The Pathogenesis of Vascular Disease. Textbook of Angiology. New York: Springer-Verlag; 1999:787-798.
- Flier JS, et al. Severely impaired adipsin expression in genetic and acquired obesity. Science, 1987; 237: 405-408
- Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell. 1995; 80:15-18.
- Flier JS: Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004; 116: 337–350.
- Folsom AR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI- 1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162–169
- Forman BM, et al. 15-deoxyprostaglandin J2 is a ligand for the adipocyte determination factor PPARy. Cell 1995; 83, 803-812
- Forst T, et al. Pleiotropic and anti-inflammatory effects of pioglitazoneglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008; 197: 311-317.
- Freeman DJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-600.
- Fried SK, et al. Omental and subcutaneous adipose tissues of obese subjects release interleukin6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83:
  847–850

Friedman J. Fat in all the wrong places. Nature 2002, 415:268–269.

- Fruzzetti F, et al. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 2002; 77:936–944.
- Fukuhara A, et al Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430
- Garbriely I, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002; 51: 2951–2958.
- Garg A. Lipodystrophies. Am J Med. 2000;108:143-52.

- Garlichs CD, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-2400.
- Gary-Boboo M et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471–478.
- Gasperi V, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell. Mol. Life. Sci. 2007; 64: 219-229.
- Gaziano JM. Epidemiology of risk factor reduction. In: Vascular Medicine, edited by Loscalzo J, Creagher M, and Dzau V. Boston, MA: Little Brown, 1996; p. 569–586.
- Gearing AJH, et al. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1. Pathological significance. Ann N Y Acad Sci 1992, 667:324–331.
- Gerhardt CC, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2001; 175: 81-92.
- Gerstmayer B, et al. Identification of RELM gamma, a novel resistin-like molecule with a distinct expression pattern. Genomics 2003; 81: 588–595.
- Ghanim H, et al. Circulating mononuclear cells in the obese are in a proinfl ammatory state. Circulation, 2004; 110:1564–1571.
- Ghanim H, et al. Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics. J Clin Endocrinol Metab 2006; 91: 3553–3558.
- Ghanim H, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306–1312.
- Giacchetti G, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15:381–388.
- Giltay EJ, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998; 18: 1716-1722.
- Giugliano G, et al. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg 2004; 57: 190-194.
- Gordon T, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707–714
- Gotto AM Jr and Farmer JA. Risk factors for coronary artery disease. In: Heart Disease: A Textbook of Cardiovascular Medicine, edited by Braunwald E. Philadelphia, PA: Saunders, 1988, p.1153–1190.
- Gotto AM Jr and Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on

Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 1999; 99: E1-E7

- Graham TE, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.
- Greenberg AS, et al. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res 1992; 52: 4113–4116.
- Gregoire FM, et al. Understanding adipocyte differentiation. Physiol Rev. 1998; 78: 783-809.
- Griendling KK, et al. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension. 1997; 29: 366–373.
- Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595–2600.
- Gu L, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in lowdensity lipoprotein-deficient mice. Mol Cell. 1998; 2: 275-281.
- Gustafson B, et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–2283,
- Gustafson B, Smith U. Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3–L1 preadipocytes. J Biol Chem. 2006; 281: 9507–9516.
- Gustafson B, Smith U. Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem 2006; 281: 9507–9516
- Haffner SM, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical disease? JAMA 1990; 263: 2893–2898
- Haffner SM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106: 679–684.
- Halaas JL, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543–546.
- Hammarstedt A, et al. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drugnaïve type 2 diabetic subjects. J. Intern Med. 2008; 263: 440-449.
- Hammarstedt A, et al. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun. 2003;301:578–582.
- Hammond EC and Horn D. Smoking and death rates: report on forty-four months of follow-up of 187,783 men. 2. Death rates by cause. J Am Med Assoc 1958;166: 1294–1308

- Hamsten A, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
- Han SH, et al. Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies. *Prog Cardiovasc Dis* 2009; 52:126-140.
- Hansson G, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. New York, NY: Lippincott-Raven; 1996:557–568.
- Hardardo I, et al. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5: 207-215.
- Hauer AD, et al. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr KO mice. Cardiovasc Res. 2006; 69: 280–288.
- Havel PJ, et al. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996, 81:406-413.
- Heilbronn LK, et al. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arteioscler Thromb Vasc Biol 2001; 21: 968-970.
- Heinonen MV, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul. Pept. 2005;130, 7–13.
- Herder C, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569-4574.
- Hernandez-Presa M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor- B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95:1532–1541.
- Hevener AL, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest, 2007; 117:1658–1669.
- Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature, 2002 ; 420:333– 336.
- Holcomb IN, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19: 4046-4055.
- Hotamisligil GS, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science. 1993; 259: 87–91.
- Hotamisligil GS, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95: 2409–2415.

- Hotamisligil GS, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF alpha- and obesity-induced insulin resistance. Science 1996, 271:665–668.
- Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27: S53–S55.
- Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes. 1999; 107: 119-25.
- Hotta K, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.
- Hotta K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
- Howard JK, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999; 104: 1051-9.
- Hsueh, W.A. and Law, R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1891–1895
- Hu E, et al. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996; 271, 10697–10703.
- Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999, 31:626–631.
- Hulley S, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
- Inadera H, et al. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res 1999; 19: 1179-1182.
- Ingelsson E, et al. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 2009; 204: 23–25
- Inouye KE, et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes, 2007; 56: 2242–2250.
- Isobe T, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-98.
- Itoh K, et al. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 2002; 25: 881–886.
- Iwaki M, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52, 1655–1663.
- Iwashima Y, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.

- Janke J, et al. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5.
- Jia SH, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis J. Clin. Invest. 2004; 113, 1318-1327
- Jia W, et al. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 3224-3229.
- Jiao P, and Xu H. Adipose infl ammation: cause or consequence of obesity-related insulin resistance. Diabetes, Metabolic Syndrome and Obesity 2008:1 25–31.
- Juhan-Vague I, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
- Jung HS, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. *Cardiovascular Research* 2006; 69: 76 85.
- Kahn R, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28: 2289–2304.
- Kahn SE, et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840–846.
- Kamei N, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem, 2006; 281:26602–26614.
- Kanaya AM, et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006; 91: 5044-5050.
- Kanazawa A, et al. Wnt5b partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis in 3T3–L1 preadipocytes. Biochem Biophys Res Commun. 2005; 330: 505–510.
- Kanda H, et al. MCP-1 contributes to macrophage infi Itration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 2006; 116:1494–505.
- Kaser S, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. FEBS Lett 2003; 309: 286-290.
- Kato K, et al. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 2000; 49: 662–665.
- Katsuki A, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83: 859–862.
- Katsuki A, et al. Troglitazone reduces plasma levels of tumor necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2000, 2:189–191.
- Kawanami D, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415–419.

- Kellerer M, et al. Circulating TNF-alpha and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity. Horm Metab Res 1996; 28: 737-743.
- Kern PA, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745-E751.
- Kiechl S, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103:1064.
- Kim CS, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes 2006; 30: 1347-1355.
- Kim JK, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem. 2000; 275: 8456-8460.
- Kim JK, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-446.
- Kim KH, et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J biol chem 2001; 276, 11252-11256.
- Kimura M, et al. T lymphopenia in obese diabetic (db/db) mice is non-selective and thymus independent. Life Sci 1998; 62:1243–50.
- King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol. Ther. 2002; 4: 145–151.
- Kintscher U, et al. T-lymphocyte Infiltration in Visceral Adipose Tissue. A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance. Arterioscler Thromb Vasc Biol. 2008; 28:1304-1310
- Kirkham TC, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550–557.
- Kistorp C, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
- Kleemann R, et al. Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E Knockout Mice. Circulation 2007;116: 2173-2181.
- Klo" ting N, et al. Serum Retinol-Binding Protein Is More Highly Expressed in Visceral than in SubcutaneousAdipose Tissue and Is a Marker of Intra-abdominal Fat Mass. Cell Metabolism 2007; 6: 79–87.
- Koerner A, et al. Adipocytokines: leptin the classical. Resistin the controversical, adiponectin – the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19: 525– 546.
- Konstantinides S, et al. Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533–1540.

Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.

- Kopp HP, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-1047.
- Koshiyama H, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001; 86: 3452–3456.
- Kralisch S, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185: R1-8.
- Kranzhofer R, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623–1629.
- Kumada M, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
- Kusminski CM, et al. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin. Sci. (Lond) 2005; 109, 243–256.
- Kwon K, et al. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol 2005; 101: 385-390.
- Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-869.
- La Cava A. & Matarese, G. The weight of leptin in immunity. Nature Rev. Immunol. 2004; 4, 371– 379.
- Lacasa D, et al. Macrophage-Secreted Factors Impair Human Adipogenesis: Involvement of Proinflammatory State in Preadipocytes. Endocrinology 2006; 148: 868–77.
- Lam QLK, et al. Involvement of leptin signaling in the survival and maturation of bone marrowderived dendritic cells. Eur J Immunol 2006; 36: 3118–3130.
- Lau DCW, et al. Adipokines: molecular links between obesity and atheroslcerosis Am J Physiol Heart Circ Physiol 2005; 288: H2031–H2041.
- Lavie CJ, et al. Obesity and Cardiovascular Disease. Risk Factor, Paradox, and Impact of Weight Loss. J Am Coll Cardiol, 2009; 53:1925-32.
- Lawlor DA, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90: 5677-5683.
- Lawn RM, et al. The Tangier disease gene product ABC1 controls the cellular apolipoproteinmediated lipid removal pathway. J Clin Invest 1999; 104: R25–R31
- Lee GH, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635.
- Lee J, et al. Saturated fatty acids but not unsaturated fatty acids induce the expression of COX-2 mediated through Toll like receptor 4. J. Biol. Chem 2001; 276:16683-16689.

- Lee JW, et al. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity 2007; 15: 2225-2232.
- Lee JY, et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem, 2001; 276:16683–16689.
- Lehr HA, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914.
- Lehrke M, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: e45.
- Lemieux I, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961-7.
- Li AC, et al. 2000. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:523–531.
- Li H, et al. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler Thromb. 1993; 13: 197– 204.
- Li H, Sun B. Toll-like receptor 4 in atherosclerosis J Cell Mol Med. 2007;11: 88-95.
- Li S, et al. Enhanced Proatherogenic Responses in Macrophages and Vascular Smooth Muscle Cells Derived From Diabetic db/db Mice. Diabetes 2006; 55: 2611–2619
- Libby P, et al. Inflammation and Atherosclerosis. Circulation. 2002;105:1135-1143.
- Libby P, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996; 7: 330– 335.
- Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104: 365–372.
- Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
- Lim S, et al. Insulin-Sensitizing Effects of Exercise on Adiponectin and Retinol-Binding Protein-4 Concentrations in Young and Middle-Aged Women, J. Clin. Endocrinol. Metab. 2008; 93: 2263-2268.
- Lin Y, et al. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem. 2000; 275: 24255–24263.
- Lindsay RS, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: e15-6.
- Lindsay RS, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
- Lion CJ, et al. Mini Review; Adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200.
- Loffreda S, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998;12: 57-65,

- Longo KA, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem. 2004; 279 :35503–35509.
- Lord GM, et al. Leptin modulates the T-cell immune response and reverses starvation- induced immunosuppression. Nature 1998; 394: 897–901.
- Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
- Lu SC, et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Letters. 2002; 530, 158-162
- Lumeng CN, et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest, 2007;117: 175–184.
- Lundgren M, et al. Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia. 2007; 50: 625-633.
- Luo et al. Macrophage Adiponectin Expression Improves Insulin Sensitivity and Protects Against Inflammation and Atherosclerosis. Diabetes 2010; 59:791-799.
- Mach F, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999; 104: 1041–1050.
- MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774
- Madonna R, et al. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004; 47:532–536.
- Maeda K, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 1996; 221, 286–289.
- Maeda N, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Med. 2002; 8: 731–737.
- Maeda N, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094–2099.
- Maeda N. et al. Diet induced insulin resistance in mice lacking adiponectin/ACRP30, Nat Med. 2002; 8: 731-737.
- Mancuso P, et al. Leptin augments alveolar macrophage leukotriene synthesis by increasing phospholipase activity and enhancing group IVC iPLA2 (cPLA2gamma) protein expression. Am J Physiol Lung Cell Mol Physiol 2004; 287: 497–502.
- Mannino, D. M. et al. Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY). Int. J. Obesity (Lond). 2006; 30, 6–13.

- Marcil M, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354: 1341–1346
- Marx N, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003, 107: 1954–1957.

Matarese G, et al. Leptin in immunology. J Immunol 2005;174:3137-3142.

- Matias I et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171–3180.
- Matsushita K, et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006; 26: 871-876.
- Matsuzawa Y, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29 –33.
- Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:35–42.
- McGill HC Jr, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation* 2002:105:2712–2718.
- McGill JB, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104–109.
- McGill JB, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109.
- Medzhitov R, et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997; 388: 394–397.
- Medzhitov R, Janeway CJ. The Toll like receptor family and microbial recognition, Trends Microbiol. 2000; 8: 452-456
- Megawa H, et al. Short term low dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J 2007; 54: 613-618.
- Mertens I, et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001; 33: 602-607.
- Michelsen KS, et al. TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis. J. Immunol.2004; 173; 5901-5907
- Miner JL. The adipocyte as an endocrine cell. J Anim Sci 2004;82: 935-941.
- Mittra S, et al. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol 2007; 150: 480–487.
- Mohamed-Ali V, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.

- Mohanty P, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol.Metab. 2004; 89: 2728-2735.
- Mohapatra J, et al. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. *J Pharm pharmacol* 2009; 61: 1493-1498.
- Moldes M, et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/betacatenin signalling during adipogenesis. Biochem J. 2003;376:607–613.
- Moller DE. Potential role of TNF- $\alpha$  in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11: 212–217
- Montague CT, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. *Diabetes* 1998; 47:1384-1391
- Moore GBT, et al. Differential regulation of adipocytokine mRNA by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2001; 286: 735–741.
- Morimoto Y, et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci, 1997; 61:795–803.
- Morise T, et al. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995, 18:87--89.
- Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001; 24: 163-76.
- Moschen AR, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748–1758.
- Motoshima H, et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315: 264 –71.
- Mussa FF, et al. Chlamydiapneumoniae and vascular disease: an update. J Vasc Surg. 2006; 43:1301–1307.
- Nabipour I, et al. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study. Cardiovasc Diabetol. 2006; 5: 25.
- Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001, 285:561–564.
- Nagel T, et al. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest. 1994; 94: 885–891.
- Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5:379–387.
- Neumeier M, et al. Different effects of adiponectin isoforms in human monocytic cells. J. Leukocyte Biol. 2006; 79, 803–808.

- Ni M, et al. Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice. Am J Physiol Heart Circ Physiol 2009; 296: H1598-H1606
- Nishigaki I, et al. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 1981; 25: 373–378.
- Nissen SE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008; 299: 1547-1560.
- Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: Molecular mechanism and clinical implications. *Clin Sci* (Lond) 2009; 117: 95-109.
- Nogueiras R, et al. Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57: 2977-91.
- Nolan JJ, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188–1193.
- Nomura S, et al. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000; 121: 437-443.
- O'st A, et al. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J. 2007; 21: 3696 –3704.
- O'Connor JC, et al. IL-1 -mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. J Immunol 2005; 174: 4991-4997
- O'Rourke L, et al. Glucosedependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277: 42557–42562.
- O'Rourke RW, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity, Clinical and Experimental Immunology, 2006; 146: 39–46
- Oberkofler H, et al. Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J Lipid Res. 1997;38: 2125–2133.
- Odegaard JI, et al. Macrophage specifi c PPARgamma controls alternative activation and improves insulin resistance. Nature, 2007; 447:1116–1120.
- Okamoto Y, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106: 2767–2670.
- Ong KK, et al. Sex-discordant associations with adiponectin levels and lipid profiles in children. Diabetes 2006; 55: 1337-1341.
- Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta 2000;1529: 321-330.
- Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298–1305.
- Otero M, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005;579: 295–301.

÷ 1

- Otero M, et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006;45: 944–950.
- Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol. 2005;40:229–242.
- Ouchi N, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296–1301
- Ouchi N, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
- Ouchi N, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100, 2473–2476.
- Ouchi N, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674.
- Pacher P, and Ungvári Z. Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. Am J Physiol Heart Circ Physiol. 2008; 294: H1133–H1134.
- Packard RR and Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24–38.
- Pagano C, et al. Reduced Plasma Visfatin/Pre-B Cell Colony-Enhancing Factor in Obesity Is Not Related to Insulin Resistance in Humans. J. Clin. Endocrinol. Metab. 2006; 91: 3165– 3170.
- Pagano C, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J. Clin. Endocrinol. Metab. 2007; 92: 4810-4819.
- Pajvani UB, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
- Pajvani, UB. et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione -mediated improvement in insulin sensitivity. J. Biol. Chem. 2004; 279: 12152–12162
- Pang S, Le Y. Role of Resistin in inflammation and inflammation related diseases. Cell Mol Immunol 2006; 3: 29–34.
- Paolisso G, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 1995; 38:1213–1217.
- Papayianni A, et al. Circulating levels of ICAM-1, VCAM-1 and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia and vascular events. Nephrol Dial Transplant 2002; 17: 435-441.

- Parissis JT, et al. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol 2000; 85: 777-779.
- Patel L, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472–476.
- Perseghin G, et al. Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. J Clin Endocrinol Metab 2007; 92: 4883-4888.
- Persson J, et al. Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages. Lipids in Health and Disease 2006, 5:17
- Pfeiffer A, et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 1997; 29: 111-114.
- Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
- Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27:813–23.
- Piemonti L, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003; 26: 2883-2889.
- Pilz S, et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91: 4277-4286.
- Pilz S, et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005; 90: 4792-4796.
- Pineiro, R. et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005; 579, 5163–5169
- Pischon T, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13: 1764-1771.
- Pischon T, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
- Pi-Sunyer FX, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761–775.
- Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TIr4 gene. Science, 1998; 282:2085–2088.
- Popa C, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007; 48:751–762.

- Poulain Godefroy O, Froguel P. Preadipocyte response and impairment of differentiation in an inflammatory environment. Biochemical Biophysical Research Communication 2007; 356: 662-667.
- Pradhan AD, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334.
- Primrose JN, et al. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399.
- Pyorala K, et al. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab 1987; Rev 3: 463–524.
- Qi Q, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007; 92: 4827-4834.
- Qiao JH, et al. Role of macrophage colonystimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol. 1997;150:1687–1699.
- Quadro L, et al. Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. *Mol Aspects Med* 2003; 24: 421–430.
- Rabe K, et al. Adipokines and Insulin Resistance. Mol Med, 2008, 14: 741-751
- Rajala MW, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 11: 225–230.
- Rajala MW, Scherer PE. Minireview: The adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765–3773.
- Raso GM, et al. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A. 1. Br J Pharmacol 2002;137: 799–804.
- Reddy MA, et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem 2006; 281:13685–13693.
- Reilly MP, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
- Reitman ML, et al. Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. Ann N Y Acad Sci. 1999; 892:289 –296.
- Remesar X et al. Effect of oral oleoyl-estrone on adipose tissue composition in male rats. Int J Obes 2002; 26: 1092–1102.
- Reyes MR, Lazalde B. Aortic preadipocyte differentiation into adipocytes induced by rosiglitazone in an in vitro model. In Vitro Cell Dev Biol Anim. 2007; 43:159-161.
- Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836–843.

- Ridker PM, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391-397.
- Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130: 933–937.
- Rimm EB, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. *Am J Epidemiol* 1995; 141: 1117–1127.
- Robinson LJ, et al. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 995–998.
- Romano M, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:1–20.
- Rosen ED, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611–617.
- Rosen ED, et al. Transcriptional regulation of adipogenesis. Genes Dev. 2000;14:1293-1307
- Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006; 7: 885–896.
- Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145–171.
- Rosen ED. The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids. 2005; 73: 31–34.
- Rosenson RS: Assessing risk across the spectrum of patients with the metabolic syndrome. Am J Cardiol 2005; 96:8E-10E
- Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115-126.
- Ross SE, et al. Inhibition of adipogenesis by Wnt signaling. Science. 2000;289:950-953.
- Rotter V, et al. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777–45784
- Roytblat L, et al. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8: 673-675,
- Rucker D, et al. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. Br Med J 2007; 335:1194–1199.
- Rust S, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352– 355
- Ryden M, et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem. 2002; 277:1085–1091.
- Saijo S, et al. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem. Biophys. Res. Commun. 2005; 334, 1180–1183.

- Salmenniemi U, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842-3848.
- Samad F, et al. Elevated expression of transforming growth factor-alpha in adipose tissue from obese mice. Mol Med 1997; 3:37–48
- Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568–582
- Sandouk T, et al. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol Cell Physiol 1993; 264: C1600-C1608.
- Sanna V, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111:241–250.
- Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265–70
- Savage DB, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferatoractivated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202.
- Schafer A, et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. *Br J Pharmacol* 2008; 154: 1047–1054.
- Schafer K, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol, 2004; 24:112-117.
- Scheen AJ, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660–1672.
- Scherer PE, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995; 270, 26746–26749.
- Schiffrin EL. Beyond blood pressure: the endothelium and atherosclerosis. Am J Hypertens 2002;15:115S-22S.
- Schmidt AM, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999; 84:489–497.
- Schreyer SA, et al. Obesity and diabetes in TNF-alpha receptor- defi cient mice. J Clin Invest, 1998; 102:402–411.
- Schwartz MW, et al. Central nervous system control of food intake. Nature 2000; 404: 661-671.
- Semple RK, et al. Expression of the thermogenic nuclear hormone receptor coactivator PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects. Int J Obes Relat Metab Disord. 2004; 28: 176–179.

- Senolt L, et al. Resistin is abundantly present in rheumatoid arthritis synovial tissue, synovial fluid, and elevated serum resistin reflects disease activity. Ann Rheum Dis 2007; 66: 458–63.
- Shadid S, et al. Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 2006; 91: 3418-3425.
- Shao D, Lazar MA: Peroxisome proliferator activated receptor y, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 1997; 272: 21473-8.
- Shetty GK, et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
- Shi H, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest, 2006; 116: 3015–3025.
- Shimomura I, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999; 401:73–76.
- Sierra-Honigmann MR, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683–1386.
- Silha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-335.
- Skurk T, et al. Relationship between adipocytes size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023–1033.
- Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-64.
- Smith JD, et al. Decreased atherosclerosis in mice deficient in both macrophage colonystimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92: 8264-8268.
- Solini A, et al. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens 2009; 22: 948-949.
- Soltis EE and Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens 1991; 13: 277–96,
- Son MH, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. International Journal of Obesity 2010; 34: 547–556
- Sopasakis VR, et al. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res. 2004;12:454–460.

- Sorrentino MJ: Implications of the metabolic syndrome the new epidemic. Am J Cardiol 2005; 96:3E-7E
- Sowers JR Obesity as a cardiovascular risk factor. Am J Med 2003; 115: 37S-41S.
- Srinivasan K, et al. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 2004; 26: 327-33.
- Staiger H, et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003; 11: 368-372.
- Statnick MA, et al. Decreased expression of apM-1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int. J. Exp. Diabetes. Res. 2000; 1: 81-8.
- Stefan N, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007; 30: 1173-1178.
- Stefan N, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888.
- Steinberg BA, Cannon CP. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol 2007; 100: 27–32.
- Steinberg HO, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230–1239.
- Stejskal D, et al. Resistin- concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147: 63-69.
- Stephens JM, Pekala PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991, 266:21839–21845.
- Steppan CM, et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
- Stokes KY, et al. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009; 296:H1281-H1288.
- Stoll LL, et al. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006; 12: 4229–4245
- Straczkowski M, et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002; 87: 4602-4606.
- Strassmann G, et al. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993, 5: 285–290.
- Strissel KJ, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes, 2007; 56: 2910–2918.

.

- Stuart P, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–1808.
- Suganami T, et al. A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes Role of Free Fatty Acids and Tumor Necrosis Factor alpha. Arterioscler Thromb Vasc 2005; 25:2062-2068.
- Takashima N, et al. Retinol-Binding Protein 4 and Insulin Resistance. N Engl J Med 2006; 355:1392.
- Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells 6: 2001; 733–42
- Tang QQ, et al. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci U S A. 2003; 100: 44–49.
- Tchernof A, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105: 564-569.
- Thorne A, et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. International J Obesity. 2002; 26: 193–199.
- Tian Z, et al. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002; 298: 297–302.
- Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772–783.
- Tominaga M, et al. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 1993; 40: 343–349.
- Tonelli, J. et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621–1629
- Tontonoz P, et al. mPPAR gamma 2: tissuespecific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224–1234.
- Tontonoz P, et al. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 1995; 5: 571–576.
- Tontonoz P, et al. Stimulation of adipogenesis in fibroblasts by PPAR y 2, a lipid-activated transcription factor. Cell. 1994; 79:1147-56
- Trillou CR, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284: R345–R353.
- Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179–190
- Tschritter O, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-243.

- Tsukumo DM, et al. Loss-of function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes, 2007; 56:1986–1998.
- Tsutsumi C, et al. Retinoids and retinoid-binding protein expression in rat adipocytes. *J Biol Chem*1992; 267:1805-1810.
- Tuomainen AM, et al. Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microbial Pathogenesis 2008; 44: 111–117.
- Ueki et al. Suppressor of Cytokine Signaling 1 (SOCS-1) and SOCS-3 Cause Insulin Resistance through Inhibition of Tyrosine Phosphorylation of Insulin Receptor Substrate Proteins by Discrete Mechanisms. Molecular and Cellular Biology 2004; 24: 5434-5446.
- United States Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. Report Surgeon General 1989; DHSS CDC 89–8411
- Usui S, et al. Association between serum retinol-binding protein 4 and small dense low-density lipoprotein cholesterol levels in young adult women. *Clin Chim Acta* 2009; 399: 45–48.
- Uysal KT, et al. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alphamediated insulin resistance in genetic obesity. Endocrinology,1998; 139: 4832–4838.
- Uysal KT, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 1997; 389: 610–614.
- Vaisse C, et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1999;14: 95–99,
- Van Gaal et al. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
- Van Gaal LF, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389–1397.
- Van Gall L et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/ obese patients. Diabetes Care 2008; 31: S229–S240.
- Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78.
- Ventre J, et al. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997, 46:1526–1531.
- Verma S, et al. Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction. Circulation 2003;108: 736–740.
- Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension. Curr Opin Nephrol Hypertens 2003;12:181–7.
- von Eynatten M, et al. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 2008; 29: 1307-1315.

- von Eynatten M, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007; 50: 1930–1937
- Vozarova B, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-417.
- Wang P, Ba ZF, and Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol 1994; 266: H2535– H2541.
- Way et al. Adipose Tissue Resistin Expression Is Severely Suppressed in Obesity and Stimulated by Peroxisome Proliferator-activated Receptor g Agonists. The J Biol Chem 2001; 276: 25651–25653.
- Weisberg SP, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006; 116, 115–124.
- Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
- Wellen, KE. & Hotamisligil, GS. Inflammation, stress, and diabetes. J. Clin. Invest. 2005; 115, 1111–1119
- Wendt T, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185: 70 –77.
- Weyer C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type ii diabetes independent of insulin resistance. Diabetologia. 2000; 43:1498 –1506.
- Wiedermann CJ, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J. Am. Coll. Cardiol. 1999; 34: 1975.
- Wilkison WO, et al. Control of the adipsin gene in adipocyte differentiation. Identification of distinct nuclear factors binding to single- and double-stranded DNA. J Biol Chem. 1990; 265: 477-482.
- Williams L, et al. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004;172:567–576.
- Wilson PW, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104–1109.
- Wilson PW, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847,
- Wilson-Fritch L, et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol. 2003; 23:1085–1094.

- Winer JC, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4415-4423.
- Wolf A.M. et al. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J. Hepatol. 2006; 44, 537–543.
- Wolf AM, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004; 323, 630–635
- Wu Z, et al. Cross-regulation of C/EBP alpha and PPAR γ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999;3: 151–8.
- Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112:1821–1830.
- Yamaguchi N, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005; 579, 6821–6826.
- Yamauchi T, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941–946.
- Yamauchi T, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 946-9.
- Yamauchi T, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 946-949.
- Yamuchi T. et al. Globular adiponectin protected ob/ob mice from diabetes and apoE deficient mice from atherosclerosis. J. Biol. Chem, 2003; 278: 2461-2468.
- Yang Q, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes, Nature 2005; 436: 356-362.
- Yang WS, et al. Weight reduction increases plasma levels of an adipose-derived antiinflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
- Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50:1127–1139.
- Yannakoulia M, et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resitin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736.
- Yao-Borengasser A, et al. Retinol Binding Protein 4 Expression in Humans: Relationship to Insulin Resistance, Inflammation, and Response to Pioglitazone. J Clin Endocrinol Metab 2007; 92: 2590–2597.
- Ye SQ, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury Am. J. Respir. Crit. Care Med. 2005; 171,361-370.
- Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med. 2004; 351, 1106–1118

- Yokota T, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723–1732.
- Yu JG, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51:2968–2974.
- Yuan M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk beta. Science, 2001; 293:1673–1677.
- Yudkin JS, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19: 972–978.
- Yudkin JS, et al. Inflammation, obesity, stress and coronary heart disease: is interlukin- 6 the link? Atherosclerosis 2000; 148: 209-214.
- Zarkesh-Esfahani H, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001;167: 4593–4599.
- Zhang B, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271: 9455–9459
- Zhang JL, et al. Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 2003; 20: 828-831.
- Zhang Q, et al. Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza. Phytother Res 2008; 22:1040-1045.
- Ziccardi P, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105: 804–809

Zykova SN, et al. diabetic type II-like db/db mice. Diabetes 2000; 49:1451-1458.